Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Descending Age Study of P2VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers and Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* healthy infants/toddlers as established by medical history and clinical examination before entering study~* age:~  * toddler cohort: \> or = 2 and \<3 years old at the time of enrollment~ * infant cohort: \> or = 6 and \<8 weeks at the time of enrollment~* parental ability and willingness to provide informed consent~* parental intention to remain in the area with the child during the study period.~Exclusion Criteria:~* Presence of fever on the day of enrollment~* Acute disease at the time of enrollment~* Concurrent participation in another clinical trial throughout the entire timeframe for this study~* Presence of malnutrition or any systemic disorder (cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrine, immunological, dermatological, neurological, cancer or autoimmune disease) as determined by medical history and/or physical examination that would compromise the participant's health or is likely to result in nonconformance to the protocol~* For infant cohort, history of premature birth (\<37 weeks gestation)~* History of congenital abdominal disorders, intussusception, or abdominal surgery~* Known or suspected impairment of immunological function based on medical history and physical examination~* For infant cohort only, prior receipt of rotavirus vaccine~* A known sensitivity or allergy to any components of the study vaccine~* History of anaphylactic reaction~* Major congenital or genetic defect~* Participant's parents not able, available or willing to accept active weekly follow-up by the study staff~* Has received any immunoglobulin therapy and/or blood products since birth or planned administration during the study period~* History of chronic administration (defined as more than 14 days) of immunosuppressant medications, including corticosteroids. Infants on inhaled or topical steroids may be permitted to participate in the study~* Any medical condition in the parents/infant that, in the judgment of the investigator, would interfere with or serves as a contraindication to protocol adherence or a participant's parents' ability to give informed consent~* HIV infection~  * For toddlers, to be assessed by HIV ELISA~ * For infants, to be assessed by PCR, if mother is not known to be negative (negative test result between 24 weeks gestation and screening)

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 35 Months
- Healthy Volunteers: t

Study Arms:
- Cohort A P2-VP8 30 mcg (Type: EXPERIMENTAL): Cohort A toddlers (24-35 mo) receiving P2-VP8 Subunit Vaccine (30 mcg)
- Cohort A Placebo (Type: PLACEBO_COMPARATOR): Cohort A toddlers (24-35 mo)
- Cohort A P2-VP8 60 mcg (Type: EXPERIMENTAL): Cohort A toddlers (24-35 mo) receiving high dose P2-VP8 Subunit Vaccine (60mcg)
- Cohort B P2-VP8 10mcg (Type: EXPERIMENTAL): Cohort B infants receiving P2-VP8 Subunit Vaccine (10mcg)
- Cohort B placebo (Type: PLACEBO_COMPARATOR): Cohort B infants aged 6 to \< 8 weeks receiving placebo
- Cohort B P2-VP8 30mcg (Type: EXPERIMENTAL): Cohort B infants aged 6 to \< 8 weeks receiving P2-VP8 Subunit Vaccine (30mcg)
- Cohort B1 P2-VP8 60mcg (Type: EXPERIMENTAL): Cohort B1 Infants aged 6 to \< 8 weeks receiving P2-VP8 Subunit Vaccine (60mcg)
- Cohort A P2-VP8 10mcg (Type: EXPERIMENTAL): Cohort A toddlers (24-35 mo) receiving P2VP8 Subunit Vaccine (10mcg)

Based on this trial design, predict the completion outcome and termination type (if applicable).